UMIN-CTR History

Name：　　UMIN ID：


Unique ID issued by UMIN UMIN000002365
Receipt number R000002871
Scientific Title A phase III randomized study of neoadjuvant chemotherapy including trastuzumab + cyclophosphamide + docetaxel in patients with operable HER2 positive breast cancer (JBCRG 10)
Date of disclosure of the study information 2009/08/31
Last modified on 2021/08/06 11:40:36

No. Disposal Last modified on Item of update
1 Insert 2009/08/21 14:49:57
2 Update 2009/11/05 17:17:09 Organization2
Address2
Tel2
Email2
3 Update 2009/11/10 16:51:48 Address
4 Update 2009/11/16 15:36:54 UMIN ID1
5 Update 2009/11/18 11:41:48 Recruitment status
6 Update 2011/08/12 12:15:23 Last follow-up date
7 Update 2011/08/12 13:50:06 Narrative objectives1
Narrative objectives1
8 Update 2011/08/17 15:20:28 Narrative objectives1
Narrative objectives1
9 Update 2011/08/24 00:38:21 Post marketing survey by drug manufacture etc., specified by Japanese law.
10 Update 2012/02/21 23:58:33 Recruitment status
11 Update 2013/09/24 10:43:28 Publication of results
Results
Results
12 Update 2013/09/24 10:45:32 Results
Results
13 Update 2016/03/23 15:07:52 Last name of lead principal investigator
Last name of lead principal investigator
Organization
Organization
Division name
Division name
Address
Address
TEL
Email
Address
Address
TEL
Address2
Tel2
Institutions
14 Update 2016/03/23 15:09:11 Recruitment status
15 Update 2016/07/08 14:58:27 Name of primary person or sponsor
Organization
16 Update 2018/08/23 15:04:37 Recruitment status
Last follow-up date
17 Update 2019/03/22 16:11:48 Recruitment status
Date of IRB
Last follow-up date
18 Update 2021/08/06 11:40:37 URL releasing protocol
Publication of results
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results
Results date posted
Date of the first journal publication of results
Baseline Characteristics
Baseline Characteristics
Participant flow
Participant flow
Adverse events
Adverse events
Outcome measures
Outcome measures